ArticleAnnals of surgery1995
The significance of c-erb B-2 and p53 immunoreactivity in patients with adenocarcinoma of the esophagus.
Article in Annals of surgery, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Pooled it
- Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma.British journal of cancer · 2015Pooled it
- Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2012Pooled it
- Phase II Feasibility and Biomarker Study of Neoadjuvant Trastuzumab and Pertuzumab With Chemoradiotherapy for Resectable Human Epidermal Growth Factor Receptor 2-Positive Esophageal Adenocarcinoma: TRAP Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2020Trial
- HER2-Directed Therapy in Advanced Gastric and Gastroesophageal Adenocarcinoma: Triumphs and Troubles.Current treatment options in oncology · 2021Review
- HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis.Journal of gastrointestinal oncology · 2014Article
- Human epidermal growth factor receptor-2 in oesophageal cancers: an observational study.World journal of gastroenterology · 2012Article
- Correlation between the pretherapeutic neutrophil to lymphocyte ratio and the pathologic response to neoadjuvant chemotherapy in patients with advanced esophageal cancer.World journal of surgery · 2012Article
- Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer.ISRN surgery · 2012Article
- Early response evaluation and prediction in neoadjuvant-treated patients with esophageal cancer.World journal of gastrointestinal surgery · 2009Article
- Chromosomal abnormalities and novel disease-related regions in progression from Barrett's esophagus to esophageal adenocarcinoma.International journal of cancer · 2009Article
- Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers.Therapeutic advances in medical oncology · 2009Article
- Predicting the response of localised oesophageal cancer to neo-adjuvant chemoradiation.World journal of surgical oncology · 2007Article
- Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in oesophageal adenocarcinoma: a tissue microarray study.Journal of clinical pathology · 2006Article
- Molecular biology of Barrett's adenocarcinoma.Annals of surgery · 2001Review
- Clinical significance of p53 mutations in adenocarcinoma of the esophagus and cardia.Annals of surgery · 2000Article
- Barrett's esophagus. The significance of p53 in clinical practice.Annals of surgery · 1997Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveStudies in breast cancer suggest that p53 and c-erb B2 protein overexpression are predictive of outcome. The authors determined whether these molecular markers correlated with treatment response and survival in patients with adenocarcinoma of the esophagus and esophagogastric junction.
methodImmunostaining for p53 and c-erb B2 was performed on paraffin-embedded specimens from 42 patients with esophageal adenocarcinoma. All patients received neoadjuvant chemotherapy (cisplatin and fluorouracil [5-FU] x 3 cycles) and irradiation (4500 rads) followed by resection.
resultsIn this cohort of patients, 79% (33/42) were positive for p53, and 43% (18/42) were positive for c-erb B2. p53 positivity correlated with residual disease in the resection specimen but not with disease-free survival. Although c-erb B2 negatively correlated with residual disease after resection and a 5-year survival of 10%, c-erb B2 positivity was associated with a 5-year actuarial survival of 60%.
conclusionsAlthough p53 protein overexpression is commonly observed in adenocarcinoma of the esophagus, its prognostic value appears limited. In contrast, c-erb B2 protein expression predicts a favorable response to therapy and improved survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.